Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 208

1.

Expanding the criteria for BRCA mutation testing in breast cancer survivors.

Kwon JS, Gutierrez-Barrera AM, Young D, Sun CC, Daniels MS, Lu KH, Arun B.

J Clin Oncol. 2010 Sep 20;28(27):4214-20. doi: 10.1200/JCO.2010.28.0719. Epub 2010 Aug 23.

PMID:
20733129
2.

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.

Kwon JS, Daniels MS, Sun CC, Lu KH.

J Clin Oncol. 2010 Feb 1;28(4):675-82. doi: 10.1200/JCO.2008.21.4684. Epub 2009 Oct 19.

PMID:
19841329
3.

Cost-effectiveness of preventive strategies for women with a BRCA1 or a BRCA2 mutation.

Anderson K, Jacobson JS, Heitjan DF, Zivin JG, Hershman D, Neugut AI, Grann VR.

Ann Intern Med. 2006 Mar 21;144(6):397-406.

PMID:
16549852
4.

Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers.

Kwon JS, Tinker A, Pansegrau G, McAlpine J, Housty M, McCullum M, Gilks CB.

Obstet Gynecol. 2013 Jan;121(1):14-24. doi: http://10.1097/AOG.0b013e3182783c2f.

PMID:
23232752
5.

Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.

Graeser MK, Engel C, Rhiem K, Gadzicki D, Bick U, Kast K, Froster UG, Schlehe B, Bechtold A, Arnold N, Preisler-Adams S, Nestle-Kraemling C, Zaino M, Loeffler M, Kiechle M, Meindl A, Varga D, Schmutzler RK.

J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.

PMID:
19858402
6.

Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.

Domchek SM, Gaudet MM, Stopfer JE, Fleischaut MH, Powers J, Kauff N, Offit K, Nathanson KL, Robson M.

Breast Cancer Res Treat. 2010 Jan;119(2):409-14. doi: 10.1007/s10549-009-0611-y.

PMID:
19885732
7.

Association between clinical characteristics and risk-reduction interventions in women who underwent BRCA1 and BRCA2 testing: a single-institution study.

Uyei A, Peterson SK, Erlichman J, Broglio K, Yekell S, Schmeler K, Lu K, Meric-Bernstam F, Amos C, Strong L, Arun B.

Cancer. 2006 Dec 15;107(12):2745-51.

8.

Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testing.

Manchanda R, Legood R, Burnell M, McGuire A, Raikou M, Loggenberg K, Wardle J, Sanderson S, Gessler S, Side L, Balogun N, Desai R, Kumar A, Dorkins H, Wallis Y, Chapman C, Taylor R, Jacobs C, Tomlinson I, Beller U, Menon U, Jacobs I.

J Natl Cancer Inst. 2014 Nov 30;107(1):380. doi: 10.1093/jnci/dju380. Print 2015 Jan.

9.

Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

Grann VR, Jacobson JS, Whang W, Hershman D, Heitjan DF, Antman KH, Neugut AI.

Cancer J Sci Am. 2000 Jan-Feb;6(1):13-20.

PMID:
10696733
10.

Evaluation of a surveillance programme for women with a family history of breast cancer.

Reis MM, Tavakoli M, Dewar J, Goudie D, Cook A, McLeish L, Young D, Kenyon J, Steel M.

J Med Genet. 2009 May;46(5):319-23. doi: 10.1136/jmg.2008.064311. Epub 2009 Mar 10.

PMID:
19279022
11.

Direct-to-patient BRCA1 testing: the Twoj Styl experience.

Gronwald J, Huzarski T, Byrski T, Debniak T, Metcalfe K, Narod SA, Lubiński J.

Breast Cancer Res Treat. 2006 Dec;100(3):239-45. Epub 2006 Jun 29.

PMID:
16807675
12.

Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.

Satagopan JM, Boyd J, Kauff ND, Robson M, Scheuer L, Narod S, Offit K.

Clin Cancer Res. 2002 Dec;8(12):3776-81.

13.

Morphology of breast cancer as a means of triage of patients for BRCA1 genetic testing.

Farshid G, Balleine RL, Cummings M, Waring P; Kathleen Cuningham Consortium for Research into Familial Breast Cancer (kConFab)..

Am J Surg Pathol. 2006 Nov;30(11):1357-66.

PMID:
17063074
14.

Decision analysis of tamoxifen for the prevention of invasive breast cancer.

Grann VR, Sundararajan V, Jacobson JS, Whang W, Heitjan DF, Antman KH, Neugut AI.

Cancer J. 2000 May-Jun;6(3):169-78.

PMID:
10882333
15.

Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.

Ishiguro H, Kondo M, Hoshi SL, Takada M, Nakamura S, Teramukai S, Yanagihara K, Toi M.

Clin Ther. 2010 Feb;32(2):311-26. doi: 10.1016/j.clinthera.2010.01.029.

PMID:
20206789
16.

BRCA-1 and BRCA-2 mutations as prognostic factors in clinical practice and genetic counselling.

Nicoletto MO, Donach M, De Nicolo A, Artioli G, Banna G, Monfardini S.

Cancer Treat Rev. 2001 Oct;27(5):295-304. Review.

PMID:
11871866
17.

Changes in body weight and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers.

Kotsopoulos J, Olopado OI, Ghadirian P, Lubinski J, Lynch HT, Isaacs C, Weber B, Kim-Sing C, Ainsworth P, Foulkes WD, Eisen A, Sun P, Narod SA.

Breast Cancer Res. 2005;7(5):R833-43. Epub 2005 Aug 19.

18.

Cost-effectiveness of testing for breast cancer susceptibility genes.

Holland ML, Huston A, Noyes K.

Value Health. 2009 Mar-Apr;12(2):207-16. doi: 10.1111/j.1524-4733.2008.00418.x. Epub 2008 Jul 18.

19.

Cancer incidence in relatives of a population-based set of cases of early-onset breast cancer with a known BRCA1 and BRCA2 mutation status.

Loman N, Bladström A, Johannsson O, Borg A, Olsson H.

Breast Cancer Res. 2003;5(6):R175-86. Epub 2003 Aug 7.

20.

Clustering of individuals with both breast and ovarian cancer--a possible indicator of BRCA founder mutations.

Einbeigi Z, Meis-Kindblom JM, Kindblom LG, Wallgren A, Karlsson P.

Acta Oncol. 2002;41(2):153-7.

PMID:
12102159

Supplemental Content

Support Center